20 articles
Italian researchers developed a biosensor to track extracellular vesicles in blood, potentially personalizing stroke rehabilitation.
A Phase 2 trial investigates whether thiethylperazine, a decades-old antiemetic, can flush toxic amyloid beta from the brains of early AD patients.
A Phase 1/2 trial tests whether dexmedetomidine can enhance the brain's glymphatic system to clear amyloid and tau during sleep.
A completed Phase 1/2 pilot trial tested whether the senolytic duo D+Q penetrates the brain in early Alzheimer's disease.
Pilot study tests psilocybin-assisted psychotherapy to help hospice patients overcome demoralization and existential suffering.
Probucol, a discontinued cholesterol medication, may boost brain-protective proteins in older adults at risk for dementia.
A Phase 4 RCT tests whether one bevacizumab injection matches two combined doses for neovascular AMD outcomes over 12 months.
Small study tests psychedelic compound's safety and effectiveness against severe depression that doesn't respond to standard treatments.
University researchers used psychedelic therapy and brain imaging to tackle cocaine addiction, revealing new neural pathways for recovery.
60-person study tested psilocybin alone and with CBT for major depression, measuring brain activity and inflammatory markers.
Nine-year study investigated whether solanezumab could slow memory decline in older adults with brain amyloid plaques.
A Phase 2 open-label trial explores whether an approved immune drug can raise frataxin protein levels and slow neurological decline in Friedreich Ataxia.
NGP 555 targets toxic brain protein production in healthy volunteers, offering potential early intervention for Alzheimer's prevention.
Large 503-patient study tested whether Actovegin could improve thinking and memory problems that persist after stroke recovery.
Small doses of psilocybin tested against placebo in 39 adults with major depressive disorder to assess safety and mood benefits.
A phase 2/3 trial of the BACE inhibitor atabecestat in amyloid-positive asymptomatic adults was terminated before completion, raising questions about this drug class.
TONTT2 tests whether erythropoietin dose and timing can be optimized to best preserve vision after traumatic optic neuropathy.
Contraloid acetate, an oral all-D-peptide designed to disassemble toxic amyloid-beta oligomers, completed its first-in-human safety trial in 40 healthy volunteers.
Personalized treatment approach targeting multiple causes of cognitive decline outperformed standard care in 9-month trial.
French pilot study tests psychedelic therapy for patients with alcohol use disorder and comorbid depression after withdrawal.
